Peptide Reclassification Is Not FDA Approval

FDA Peptide Regulation

80+ peptide drugs

More than 80 peptide drugs have completed full FDA approval, each requiring years of clinical trials. Reclassification skips this entire process.

Muttenthaler et al., Nat Rev Drug Discov, 2021

Muttenthaler et al., Nat Rev Drug Discov, 2021

View as image

In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list would move back to Category 1. Within days, headlines declared peptides were "legal again" and clinics began advertising renewed access. What most of that coverage failed to explain: reclassification to Category 1 is not the same as FDA approval. The two processes are fundamentally different in what they require, what they prove, and what they mean for anyone using these peptides.

FDA approval of a drug requires preclinical testing, Phase I through Phase III clinical trials, safety and efficacy review, manufacturing validation, and post-market surveillance. Reclassification simply moves a substance from one compounding category to another. It does not establish that a peptide is safe, effective, or tested in controlled human trials. More than 80 peptide drugs have completed this full approval process over the past century.^[1] None of the 14 reclassified peptides are among them.

What FDA Approval Actually Requires

The path from laboratory molecule to FDA-approved drug is long, expensive, and designed to fail at multiple points. Muttenthaler et al. (2021) reviewed the full pipeline in Nature Reviews Drug Discovery, documenting how peptide drug candidates move from discovery through clinical development.^[1]

The process has four major stages. Preclinical testing establishes basic pharmacology, toxicology, and dosing in animal models. Phase I trials test safety and tolerability in small groups of healthy volunteers or patients, typically 20 to 80 people. Phase II trials evaluate efficacy and side effects in larger groups, often 100 to 300 patients. Phase III trials confirm efficacy and monitor adverse reactions in large populations, sometimes thousands of participants, over months or years.

After Phase III, the manufacturer submits a New Drug Application (NDA) or Biologics License Application (BLA) containing all accumulated data. The FDA reviews manufacturing processes, labeling, and clinical evidence before granting approval. Post-market surveillance (Phase IV) continues indefinitely.

This process takes 10 to 15 years on average and costs hundreds of millions to billions of dollars. Most candidates fail. The peptides that have completed it, including semaglutide, octreotide, leuprolide, and teriparatide, have extensive human safety and efficacy data supporting their use for specific indications.

What Reclassification Actually Does

Reclassification moves a bulk drug substance between FDA compounding categories. The category system was established to organize substances that 503A (traditional) and 503B (outsourcing facility) pharmacies can use to prepare compounded medications.

Category 1 substances can be used by compounding pharmacies to prepare individualized prescriptions. This does not mean the FDA has evaluated the substance for safety or efficacy. It means the FDA has not determined that the substance presents significant safety risks that would justify prohibiting compounding.

Category 2 substances are those the FDA has flagged as presenting potential significant safety risks. While on this list, compounding pharmacies cannot use them.

The 14 peptides moving from Category 2 back to Category 1 include BPC-157, thymosin alpha-1, thymosin beta-4/TB-500, CJC-1295, ipamorelin, and others. Their return to Category 1 means licensed compounding pharmacies can prepare them again under a physician's prescription. It does not mean the FDA reviewed clinical trial data and concluded they work. The RFK Jr. announcement was a regulatory policy change, not a scientific endorsement.

The Evidence Gap: BPC-157 as a Case Study

BPC-157 is the most prominent example of the gap between reclassification and approval. Hundreds of animal studies exist, many conducted by a single research group in Croatia. But human data is extraordinarily limited.

Lee et al. (2025) published the first and only study examining intravenous BPC-157 administration in humans.^[5] It was a pilot study with 2 participants. Two people. They received 10 mg and 20 mg IV infusions over two days, with blood work and vital signs monitored. No adverse events were reported, but a study of 2 people cannot establish safety in any meaningful clinical sense. It is a starting point, not an endpoint.

Klicek et al. (2008) reported on BPC 157 in clinical trials as a therapy for inflammatory bowel disease, but that work used an oral formulation (designated PL14736) and Phase II data has not been published in peer-reviewed literature.^[6] Sikiric et al. (2025) published a comprehensive review describing BPC-157's proposed mechanisms of action across multiple organ systems, but acknowledged the evidence remains almost entirely preclinical.^[7]

Compare this to tesamorelin (Egrifta), a GHRH analog that completed full Phase III trials in hundreds of patients before FDA approval. Or semaglutide, which was studied in over 15,000 participants across the STEP and SUSTAIN trial programs before receiving FDA approval for weight management and diabetes. The evidentiary bar for approval is orders of magnitude higher than what any reclassified peptide has met.

BPC-157's full research profile is extensive in animal models but nearly nonexistent in controlled human studies. Reclassification does not change that evidence landscape. It changes only the legal status of compounding.

What Compounded Peptides Do Not Have

An FDA-approved drug comes with guarantees that compounded peptides do not provide.

Standardized manufacturing. Approved drugs are produced under Current Good Manufacturing Practice (cGMP) regulations with lot-by-lot testing, validated processes, and facility inspections. Compounded preparations are made in pharmacy settings with less oversight. Quality varies between pharmacies and between batches.

Verified purity and potency. Krug et al. (2018) analyzed black market growth-promoting peptide products and found substances with incorrect amino acid sequences, impurities, and mislabeled contents.^[2] While compounding pharmacies operate under more oversight than black market vendors, they are not held to the same standard as pharmaceutical manufacturers.

Proven dosing. FDA-approved drugs have established, evidence-based dosing regimens from clinical trials. For most compounded peptides, dosing is based on extrapolation from animal data, anecdotal clinical experience, or manufacturer recommendations without controlled trial support.

Post-market surveillance. Approved drugs are monitored through the FDA Adverse Event Reporting System (FAERS) and other pharmacovigilance programs. Chiappini et al. (2023) demonstrated how FAERS data can identify misuse patterns and adverse events for approved peptide drugs like semaglutide.^[8] Compounded peptides have no equivalent systematic monitoring.

Labeled indications. FDA approval is granted for specific medical conditions based on trial evidence. Compounded peptides have no approved indications. They are prescribed off-label by definition.

The Quality Control Problem

The distinction between FDA-approved and compounded matters most at the point of product quality. Mestria et al. (2021) analyzed melanotan II and bremelanotide products sold on the black market and found variable purity, undisclosed excipients, and products that did not match their labels.^[4]

Habbema et al. (2017) reviewed the risks of unregulated alpha-melanocyte-stimulating hormone analogues and documented adverse events including nausea, facial flushing, changes in existing moles, and cardiovascular effects.^[3] Many of these events occurred with products of uncertain composition and purity.

Licensed 503A and 503B compounding pharmacies operate under more stringent standards than gray market vendors. But "more stringent than the black market" is not the same as "equivalent to FDA-approved manufacturing." Compounded preparations do not undergo the same dissolution testing, stability testing, sterility assurance, or potency verification that approved drugs require.

The legal challenge that prompted FDA's regulatory shift was about compounding access, not about clinical evidence. The courts addressed whether the FDA's Category 2 restrictions were procedurally valid, not whether the peptides themselves had been proven safe and effective in humans.

Why the Distinction Matters for Patients

Patients encountering reclassified peptides should understand what they are and are not getting.

They are getting access to a substance that a licensed pharmacy has prepared under a physician's prescription. The legal compounding status of these peptides means that obtaining them through a pharmacy is lawful.

They are not getting an FDA-approved medication with established safety data, proven efficacy for their specific condition, standardized dosing, or manufacturing quality equivalent to commercially available drugs.

This distinction does not mean compounded peptides are inherently dangerous or that they cannot produce beneficial effects. It means the evidence supporting their use has not been subjected to the level of scrutiny that FDA approval demands. Animal studies, pilot studies of 2 people, and clinical anecdotes exist on a fundamentally different evidentiary level than Phase III randomized controlled trials.

The practical consequence: a physician prescribing a reclassified peptide is making a clinical judgment based on limited evidence, their own experience, and the patient's specific situation. This is legal and may be medically reasonable. But it is a fundamentally different scenario from prescribing an FDA-approved drug where the dosing, indications, contraindications, and expected outcomes have been established through rigorous testing.

Insurance coverage illustrates this gap directly. FDA-approved peptide drugs like semaglutide and octreotide are covered by most insurance plans because their clinical benefit has been demonstrated. Compounded peptides are almost never covered because the evidence base that insurers require for formulary inclusion does not exist. This is not an oversight. It reflects the difference in evidentiary standards between compounded and approved medications.

Patients who understand this distinction can make informed decisions about whether the available evidence, combined with their physician's clinical judgment, justifies the use of a compounded peptide for their condition. Confusing reclassification with approval removes the foundation for that informed decision.

The Eric Topol critique of the peptide industry centers on exactly this point: the gap between public enthusiasm for peptides and the clinical evidence supporting their use. Reclassification has narrowed the legal gap but has not narrowed the evidence gap.

What Would FDA Approval Require

For any of the currently compounded peptides to achieve FDA approval, they would need to complete the full regulatory pathway. For BPC-157, that would mean:

1. Formal preclinical toxicology studies meeting FDA standards (GLP-compliant)
2. An Investigational New Drug (IND) application
3. Phase I safety trials in 20-80 human subjects
4. Phase II efficacy trials in 100-300 patients with specific conditions
5. Phase III confirmatory trials in larger populations
6. An NDA or BLA submission with all accumulated data
7. FDA review of manufacturing, labeling, and clinical evidence

No reclassified peptide is currently known to be in Phase II or Phase III clinical trials for any indication. Thymosin alpha-1 comes closest, as it has been approved in some countries outside the United States under the brand name Zadaxin, but it has not completed the FDA approval pathway in the US.

The AOD-9604 GRAS status situation illustrates another common point of confusion: GRAS (Generally Recognized as Safe) status for dietary supplement use is also not the same as FDA drug approval. Different regulatory pathways create different levels of evidence and different permitted claims.

The Bottom Line

FDA reclassification of peptides from Category 2 to Category 1 restores compounding pharmacy access. It does not establish safety, efficacy, or quality equivalent to FDA-approved drugs. The 14 reclassified peptides have not completed clinical trials, do not have approved indications, and are not manufactured to the same standards as commercially available medications. Reclassification changed the legal landscape, not the evidence landscape.

Frequently Asked Questions

Is peptide reclassification the same as FDA approval?

No. FDA reclassification moves a substance from Category 2 (compounding prohibited) to Category 1 (compounding allowed). FDA approval requires Phase I, II, and III clinical trials, safety and efficacy review, and manufacturing validation. Reclassification requires none of these. More than 80 peptide drugs have completed full FDA approval; the 14 reclassified peptides have not (Muttenthaler et al., 2021).

Are reclassified peptides safe to use?

Reclassification does not establish safety. It means the FDA has not determined the substance presents significant safety risks that justify prohibiting compounding. Most reclassified peptides have extensive animal data but minimal controlled human safety data. BPC-157, for example, has only one pilot study of IV administration in 2 participants (Lee et al., 2025).

What is the difference between compounded and FDA-approved peptides?

FDA-approved peptides have completed clinical trials, have established dosing for specific conditions, are manufactured under cGMP standards with lot-by-lot testing, and are monitored through post-market surveillance. Compounded peptides are prepared by pharmacies under physician prescription without clinical trial evidence, standardized dosing, equivalent manufacturing oversight, or systematic adverse event monitoring.

Which peptides were reclassified to Category 1 in 2026?

In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that 14 of 19 peptides previously placed on Category 2 would move back to Category 1. These include BPC-157, thymosin alpha-1, thymosin beta-4 (TB-500), CJC-1295, ipamorelin, and others. Formal FDA guidance implementing this change had not been published at the time of the announcement.

Can compounding pharmacies legally make reclassified peptides?

Yes. Category 1 status allows licensed 503A compounding pharmacies to prepare these peptides pursuant to a valid prescription from a licensed healthcare provider. 503B outsourcing facilities may also compound them. This is lawful but does not make the products equivalent to FDA-approved medications in terms of evidence, manufacturing quality, or regulatory oversight.

Why do peptides need FDA approval if they can be compounded?

FDA approval establishes that a drug works for a specific condition, identifies the right dose, documents side effects, and ensures manufacturing quality. Compounded peptides bypass all of these requirements. Without clinical trials, there is no reliable evidence about optimal dosing, which conditions respond to treatment, what side effects occur at what frequency, or how the peptide interacts with other medications.